Jasper Therapeutics, Inc. JSPR
Regular-session close
After hours · Nov 19, 5:31 PM ET
- YTD
- -80.42%
- 1 year
- -80.63%
5D -2.65 (-18.71%)
- Market cap
- 11.92M
- EPS (ttm)
- -7.41
- Shares out
- 15.00M
- Forward P/E
- -4.89
- YTD return
- -80.42%
- 1-year return
- -80.63%
- 50-day average
- 21.46
- 200-day average
- 21.97
- Enterprise value
- 233.15M
- Volume
- 10.93K
- Avg volume
- 18.16K
- Open
- 10.69
- Previous close
- 11.52
- Day's range
- 10.61 – 11.50
- 52-week range
- 9.25 – 72.60
- Beta
- 2.20
- Analysts
- Strong Buy
- Price target
- 68.78 (+539.8%)
Key statistics
- Price / book
- 3.97
- Free cash flow
- -36.91M
- Total cash
- 92.50M
- Total debt
- 2.07M
- Return on equity
- -71.46%
- Short % of float
- 13.88%
Fundamental scorecard
4 of 25 checks passed on JSPR’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.09 | -1.24 | -0.15 | -13.76% |
| Aug 13, 2024 | Jun 1, 2024 | -1.09 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -1.09 | -0.97 | +0.12 | +11.01% |
| May 14, 2024 | Mar 1, 2024 | -1.26 | -1.03 | +0.23 | +18.25% |
| May 14, 2024 | Mar 1, 2024 | -1.26 | — | — | — |
| Mar 4, 2024 | Dec 1, 2023 | -1.65 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | RBC Capital | reit | Outperform | Outperform |
| Dec 6, 2024 | BMO Capital | init | — | Outperform |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 15, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Oct 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 27, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- jaspertherapeutics.com
News
Update: Jasper Therapeutics Q3 Adj. EPS $(1.05) Beats $(3.00) Estimate, Sales $8.000M Beat $3.000M Estimate
Jasper Therapeutics Q3 EPS $(10.19) Misses $(4.80) Estimate, Sales $8.000M Beat $3.000M Estimate
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Your note
Sign in to keep a note on JSPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARLYLE GROUP, INC. | Unknown | Purchase | Feb 7, 2024 | 0 |
| EMSTER KURT VON | Director | Sale | Apr 12, 2023 | 21,175 |
| FRENCH ANNA LOUISE | Director | Sale | Apr 13, 2023 | 23,750 |
| LIS WILLIAM DAVID | Director | Sale | Oct 12, 2023 | 53,521 |
| MAHAL JEETINDER SINGH | Chief Operating Officer | Conversion of Exercise of derivative security | Dec 11, 2024 | 25,009 |
| QIMING U.S. HEALTHCARE FUND II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 26, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Velan Capital Investment Management LP | 9.56% | 1,433,828 | 31.72M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 8.96% | 1,343,665 | 29.72M | Sep 29, 2024 |
| Carlyle Group Inc. | 7.11% | 1,066,189 | 23.58M | Sep 29, 2024 |
| Qiming U.s. Ventures Management, Llc | 6.19% | 928,964 | 20.55M | Sep 29, 2024 |
| Blackrock Inc. | 5.33% | 800,028 | 17.70M | Sep 29, 2024 |
| Vanguard Group Inc | 4.63% | 694,425 | 15.36M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.67% | 401,219 | 8.87M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.98% | 296,675 | 6.56M | Oct 30, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.58% | 236,841 | 5.24M | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 1.26% | 188,656 | 4.17M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.77% | 115,362 | 2.55M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.67% | 100,341 | 2.22M | Oct 30, 2024 |
